View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 23, 2021updated 12 Jul 2022 11:06am

Sanofi and Translate Bio commence Phase I influenza vaccine trial

The trial is part of the companies’ partnership to develop mRNA vaccines for various infectious diseases. 

Sanofi Pasteur and Translate Bio have commenced a Phase I clinical trial in the US to assess an investigational messenger ribonucleic acid (mRNA)-based vaccine candidate against seasonal influenza.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The monovalent flu vaccine candidate codes for the hemagglutinin protein of the influenza virus’s A/H3N2 strain.

Sanofi noted that flu seasons with the A/H3N2 strain in circulation are likely to be severe, particularly in older adults and younger children, who are at an increased risk.

The Phase I trial will analyse the safety and immunogenicity of the influenza vaccine in up to 280 subjects, with preliminary results expected by year-end.

Various dose levels of two formulations of the vaccine, MRT5400 and MRT5401, will be evaluated in healthy adults aged 18 and 49.

The formulations, which were developed by the companies, vary in the lipid nanoparticle (LNP) that comprises the mRNA.

Translate Bio CEO Ronald Renaud said: “We are pleased to have this second mRNA vaccine programme underway with our partner Sanofi Pasteur.

“We believe that mRNA technology could have several advantages for a seasonal flu application including the potential ability to demonstrate robust immune responses based on preclinical data to date, enable antigen specificity within a short timeframe from seasonal virus strain selection, and deploy agile manufacturing capacity.”

The Phase I trial comes after favourable safety and immunogenicity data were observed in preclinical studies reported in November last year.

Translate Bio signed a collaboration and exclusive licence agreement with Sanofi Pasteur in June 2018 to develop mRNA vaccines for up to five pathogens causing infectious diseases.

The companies expanded the deal in March last year, to develop a new mRNA Covid-19 vaccine.

In June last year, Translate Bio and Sanofi Pasteur agreed to create mRNA vaccines that could be used against existing and emergent infectious diseases.

At present, the companies are conducting two clinical trials of two mRNA vaccines for Covid-19 and influenza, respectively.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena